Melatonin Dosing: Why 0.1 mg Often Outperforms 10 mg for Sleep

Melatonin is one of the most over-dosed supplements in America. A 2023 analysis in JAMA (Cohen et al.; PMID 37097362) tested 25 melatonin gummy products from US retailers and found that 22 of 25 (88%) contained quantities of melatonin that did not match the label, with measured melatonin ranging from 74% to 347% of the declared dose. At the same time, the typical retail dose (3–10 mg) is 10–100× higher than what the pineal gland naturally produces at night. MIT sleep researcher Richard Wurtman's dose-response work in the 1990s and Zhdanova's follow-up trials showed that low, physiologic doses (about 0.1–0.3 mg) reliably restore endogenous melatonin levels and improve sleep onset, while much higher doses can desensitize receptors and produce a worse next-day profile.

The Dose-Response Reversal

In Wurtman's controlled trials at MIT, 0.3 mg produced peak plasma melatonin within physiologic range and improved sleep latency. At 3 mg, plasma melatonin exceeded normal nighttime levels by 10× and remained elevated well into morning — blunting next-night endogenous production and producing a morning hangover effect. Higher doses did not produce better sleep; they produced persistent receptor saturation and worse circadian alignment.

When Higher Doses Do Help

There are specific contexts where 1–5 mg is appropriate: jet lag travel, shift work sleep disorder, and certain pediatric neurodevelopmental conditions under clinical supervision. For routine sleep onset issues in healthy adults, 0.3 mg is a better starting dose with a cleaner next-morning profile.

Timing Matters More Than Dose

Melatonin is a circadian signal, not a sedative. Its effect on sleep onset is modest (about 7–10 minutes in healthy adults); its effect on circadian phase-shifting is substantial. For sleep onset, timing is 30–60 minutes before bedtime. For advancing a delayed sleep phase (night owls), taking 0.5 mg 4–6 hours before desired bedtime shifts the circadian clock earlier with each successive night.

Extended-Release vs Immediate-Release

Immediate-release melatonin addresses sleep onset. Patients whose primary complaint is sleep maintenance (waking at 3am and unable to return to sleep) often do better with a low-dose extended-release formulation, as blood melatonin falls rapidly with immediate-release products. Prolonged-release melatonin 2 mg is approved as a prescription product for insomnia in adults over 55 in Europe (Circadin), where endogenous melatonin declines with age.

Safety Tail

Melatonin is remarkably safe acutely, but chronic high-dose use in children has been associated with delayed puberty signals in animal models and remains incompletely studied long-term. For adult sleep onset, start with 0.3 mg 30 minutes before desired sleep. Increase only if no effect after two weeks. Most users never need more.